In the late 1980's, Caroni and Schwab (1) showed that the myelin membrane of oligodendrocytes is inhibiting nerve fiber growth in the central nervous system (CNS).
A monoclonal IgM antibody against an unknown CNS myelin protein later known as
Nogo-A induced substantial axonal sprouting and functional recovery in vitro and in vivo. Nowadays, the responsible neurite growth inhibitory surface protein Nogo-A and its receptors NgR1 and S1PR2 are identified and well-studied (2, 3). Nogo-A destabilizes the cytoskeleton via the rho/ROCK pathway causing growth cone collapse and inhibits neuronal growth and plasticity by down-regulation of growthassociated genes. Nogo-A suppression or neutralization leads to an increase in sprouting, axonal regeneration and neuronal plasticity and thereby to greater functional recovery after different types of CNS injuries.
In close collaboration with Novartis, a function blocking, high affinity human anti- (Figure) . The treated animals reached significantly higher scores in a variety of sensory-motor tests and showed improved recovery of locomotion and motor coordination. During the first ten days after injury, the animals were not able to void and their bladders had to be emptied manually two to three times a day. In the control antibody treated group, voiding started to recover on average around 24 days after SCI. Remarkably, voiding was restored more than one week earlier in the anti-Nogo-A antibody treated rats (6).
Suppression of Nogo-A or its receptor NgR1 enhances neurite growth in the adult CNS (2, 7). In the injured CNS, regenerative and compensatory sprouting as well as
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